• References

    Berk PD, Goldberg JD, et al. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols.
    Semin Hematol. 1986;23:132-143.

    Gilbert HS. Current management in polycythemia vera.
    Semin Hematol. 2001;38(1 Suppl 2):25-28.

    Golden C. Polycythemia vera: a review.
    Clin J Oncol Nurs. 2003;7:553-556.

    Kessler CM. Propensity for hemorrhage and thrombosis in chronic myeloproliferative disorders.
    Semin Hematol. 2004;41(2 Suppl 3):10-14.

    Munson BL. Myths & facts…about polycythemia vera.
    Nursing. 2005;35:28.

    Passamonti F, Rumi E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia.
    Am J Med. 2004;117:755-761.

    Polycythemia vera. EBSCO DynaMed website. Available at: Updated June 11, 2013. Accessed August 23, 2013.

    Ruggeri M, Tosetto A, et al. The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis.
    Ann Intern Med. 2003;139:470-475.

    Solberg LA Jr. Therapeutic options for essential thrombocythemia and polycythemia vera.
    Semin Oncol. 2002;29(3 Suppl 10):10-15.

    Spivak JL. The optimal management of polycythaemia vera.
    Br J Haematol. 2002;116:243-254.

    Stuart BJ, Viera AJ. Polycythemia vera.
    Am Fam Physician. 2004;69:2139-2144.

    Tefferi A. A contemporary approach to the diagnosis and management of polycythemia vera.
    Curr Hematol Rep. 2003;2:237-241.

    Tefferi A. Polycythemia vera: a comprehensive review and clinical recommendations.
    Mayo Clin Proc.

  • Resources

    American Society of Hematology

    The National Heart, Lung, and Blood Institute

  • Canadian Resources

    Capital Health Nova Scotia